Publications
2013
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E,
Pietra D,
Ferretti V,
Klampfl T,
Harutyunyan AS,
Milosevic JD,
Them NC,
Berg T,
Elena C,
Casetti IC,
Milanesi C,
Sant'antonio E,
Bellini M,
Fugazza E,
Renna MC,
Boveri E,
Astori C,
Pascutto C,
Kralovics R,
Cazzola M.
Blood. 2013 Dec 23. [Epub ahead of print]
2013
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.
Rumi E,
Milosevic JD,
Casetti I,
Dambruoso I,
Pietra D,
Boveri E,
Boni M,
Bernasconi P,
Passamonti F,
Kralovics R,
Cazzola M.
J Clin Oncol. 2013 Jun 10; 31(17):e269-71.
2013
Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
Rommer A,
Steinleitner K,
Hackl H,
Schneckenleithner C,
Engelmann M,
Scheideler M,
Vlatkovic I,
Kralovics R,
Cerny-Reiterer,
Valent P,
Sill H,
Wieser R.
BMC Cancer. 2013; 13: 364.
2013
Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Gisslinger H,
Schalling M,
Gisslinger B,
Skrabs C,
Müllauer L,
Kralovics R.
Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23637. [Epub ahead of print]
2013
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H,
Gotic M,
Holowiecki J,
Penka M,
Thiele J,
Kvasnicka H-M,
Kralovics R,
Petrides PE,
Gastl G,
Gisslinger B,
Muellauer L,
Schlögl E,
Indrak K,
Pytlik R,
Briere K,
Kiladjian JJ,
Beykirch M,
Gaede B,
Griesshammer M,
Herbrik-Zipp M,
Hurtz HJ,
Jacobs G,
Jäcki SH,
Keilholz U,
MezgerJ,
Schlag P,
Schriever F,
Masszi T,
Sacchi S,
Griniptì R ,Tavoriene I,
Dmoszynska A,
Hellman A,
Jedrzejczak WW,
Robak T,
SkotnickiA,
Goh YT,
Cernelc P.
Blood. 2013 March 7; 121(10): 1720–1728.
2013
Molecular basis and clonal evolution of myeloproliferative neoplasms.
Cleary C,
Kralovics R.
Clin Chem Lab Med. 2013 Oct 1; 51(10):1889-96.
2012
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A,
Milosevic JD,
Berg T,
Klampfl T,
Harutyunyan AS,
Gisslinger B,
Rumi E,
Pietra D,
Malcovati L,
Elena C,
Doubek M,
Steurer M,
Tosic N,
Pavlovic S,
Guglielmelli P,
Pieri L,
Vannucchi AM,
Gisslinger H,
Cazzola M,
Kralovics R.
Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.
2012
Clinical significance of genetic aberrations in secondary acute myeloid leukemia.
Milosevic JD,
Puda A,
Malcovati L,
Berg T,
Hofbauer M,
Stukalov A,
Klampfl T,
Harutyunyan AS,
Gisslinger H,
Gisslinger B,
Burjanivova T,
Rumi E,
Pietra D,
Elena C,
Vannucchi AM,
Doubek M,
Dvorakova D,
Robesova B,
Wieser R,
Koller E,
Suvajdzic N,
Tomin D,
Tosic N,
Colinge J,
Racil Z,
Steurer M,
Pavlovic S,
Cazzola M,
Kralovics R.
Am J Hematol. 2012 Nov;87(11):1010-6.
2012
Genetic and epigenetic alterations of myeloproliferative disorders.
Milosevic JD,
Kralovics R.
Int J Hematol. 2012 Dec 12. [Epub ahead of print].
2012
Role of germline genetic factors in MPN pathogenesis.
Harutyunyan AS,
Kralovics R.
Hematol Oncol Clin North Am. 2012 Oct;26(5):1037-51.